



A



Supplementary Figure S1. A – Three key assumptions of Mendelian randomization (MR) were used in this study: (1) the instrumental variables (genetic proxies for 12 antihypertensive drugs) are not related to the confounders (dashed line and red X); (2) the instrumental variables (genetic proxies for 12 antihypertensive drugs) are related to the exposure factor (systolic blood pressure) (solid line); and (3) the instrumental variables (genetic proxies for 12 antihypertensive drugs) are not directly related to the outcome (skin cancer) (dashed line and red X)

EUR – Europeans, EAS – East Asians, SBP – systolic blood pressure, ACEI – angiotensin-converting enzyme inhibitors, BBs – β -adrenoceptor blockers, CCBs – calcium channel blockers, ARB – angiotensin-II receptor antagonists, ANBs – adrenergic neuron blockers, Cas – centrally acting antihypertensives, LDs – loop diuretics, PSDs – potassium-sparing diuretics (PSDs) and aldosterone antagonists, Ris – renin inhibitors, AABs – α -adrenoceptor blockers, TDs – thiazides and related diuretics, Vas – vasodilator antihypertensives, CAD – coronary artery disease, Bca – bladder cancer.

B



Supplementary Figure S1. Cont. B – Flowchart of the overview of Mendelian randomization (MR) analysis

EUR – Europeans, EAS – East Asians, SBP – systolic blood pressure, ACEI – angiotensin-converting enzyme inhibitors, BBs – β -adrenoceptor blockers, CCBs – calcium channel blockers, ARB – angiotensin-II receptor antagonists, ANBs – adrenergic neuron blockers, Cas – centrally acting antihypertensives, LDs – loop diuretics, PSDs – potassium-sparing diuretics (PSDs) and aldosterone antagonists, Ris – renin inhibitors, AABs – α -adrenoceptor blockers, TDs – thiazides and related diuretics, Vas – vasodilator antihypertensives, CAD – coronary artery disease, Bca – bladder cancer.